| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8223273 | International Journal of Radiation Oncology*Biology*Physics | 2013 | 8 Pages |
Abstract
These findings suggest that the cell-killing efficacy of 212Pb-TCMC-trastuzumab after gemcitabine pretreatment may be associated with abrogation of the G2/M checkpoint, inhibition of DNA damage repair, and chromatin remodeling.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Kwon Joong PhD, Diane E. MS, Kwamena E. PhD, Martin W. PhD,